IRVINGTON, N.Y., Jan. 8, 2015 (GLOBE NEWSWIRE) -- MELA Sciences, Inc. (Nasdaq:MELA), developer of the MelaFind® system, a non-invasive software-driven image analysis device approved for use in the U.S. and the European Union to assist dermatologists in melanoma diagnosis, today announced that MELA Sciences' CEO Michael R. Stewart will present at the OneMedForum at the Marriott Marquis, San Francisco on January 13 at 2:00 p.m. PST.
One-on-one meetings are available through the OneMedConnect partnering system. Investors who cannot attend the conference can view the live webcast on OneMedTV.
A replay will be available on the Investor Relations section of the MELA Sciences home page: at MELA Sciences Investor Relations.
About the OneMedForum
The Annual OneMedForum will host nearly 100 innovative growth companies from a variety of areas. OneMedForum's objective is to assemble the most promising companies and technologies in health and medicine to connect with investors and executives.
About MelaFind (www.melafind.com)
MelaFind is the first and only medical device with FDA Pre-Market Approval (PMA) for the U.S. and Conformité Européenne (CE) Marking certification for the European Union designed to assist dermatologists in the evaluation and diagnosis of melanoma at its most curable and cost-effective stage. The MelaFind system utilizes innovative software-driven technology and state-of-the-art 3-D optical imaging to non-invasively extract data 2.5 mm below the skin surface from patient's pigmented ambiguous moles and objectively analyzes them with proprietary algorithms. MelaFind provides important additional perspective to physicians via 3-D spectral images and 100% objective data analysis to help them better understand the structural disorganization of a patient's pigmented ambiguous moles (before cutting the skin) during the evaluation and diagnosis process for melanoma.
About MELA Sciences, Inc. (www.melasciences.com)
MELA Sciences is a medical technology company dedicated to designing and developing innovative software-driven technology for physician clinical use for the early detection of skin cancer. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for their flagship product MelaFind.
CONTACT: Media Diana Garcia Redruello MELA Sciences, Inc. 914-373-6960 Investors Andrew McDonald LifeSci Advisors, LLC 646-597-6987Source:MELA Sciences